(Total Views: 477)
Posted On: 10/07/2024 8:02:34 AM
Post# of 154131
Re: Evil Rabbit #146923
Understand your concerns, Evil, and it is true that it's not a huge trial, but it's way bigger than the last time CYDY tested Leron vs. cancer.
The earlier Basket Trial tested against a variety of cancers, making it too diffuse. The update for the mTNBC trial described a total of 28 patients, but those were pooled from three different studies:
Critically, these studies used different doses.
So 60 patients in the Crc trial is not a lot, but it's a good deal more than earlier trials. Even with so few patients, the mTNBC should arguably have gotten Breakthrough Designation for the indication. I would bet that the CRC trial does win that Designation -- except that, in essence, I already have made that bet.
The earlier Basket Trial tested against a variety of cancers, making it too diffuse. The update for the mTNBC trial described a total of 28 patients, but those were pooled from three different studies:
Quote:
16 from our Compassionate Use Study, 10 from the Phase 1b/2 Study, and 2 from the Basket Study.
Critically, these studies used different doses.
So 60 patients in the Crc trial is not a lot, but it's a good deal more than earlier trials. Even with so few patients, the mTNBC should arguably have gotten Breakthrough Designation for the indication. I would bet that the CRC trial does win that Designation -- except that, in essence, I already have made that bet.
(14)
(0)
